Testing joint fluid and tissue samples to improve bone and joint disease diagnosis
Studies joint fluid and tissue samples to help diagnose inflammatory and non-inflammatory joint diseases.
Plain-language title generated from the registry record
Registry title: "Translating Articular Biomarkers Into Diagnoses"
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with joint or bone diseases that need a joint fluid sample or a joint replacement. Samples are used to test new markers that may help diagnosis.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Inflammatory or non-inflammatory bone and joint disease that needs joint fluid aspiration and/or joint replacement
- Earlier treatment
- People who had neoadjuvant therapy cannot join
Main reasons for not taking part
- Cannot speak and/or read French
- Neoadjuvant therapy
- Under tutor or curatorship
- Protected adults
- Receiving State Medical Aid
Read by machine on 12 November 2026.
Where in France
- Service de Médecine Physique et de Réadaptation, Hôpital CochinParis, FranceContact: Christelle Nguyen, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06312943
- Record updated
- 24 June 2026
- Original description
Early diagnosis is a key factor in the prevention and management of rheumatic diseases. Rheumatic diseases are classically diagnosed based on criteria combining clinical, biological and radiological features. However, in up to 20% of the cases, diagnoses remain unstated and underlying rheumatic diseases unclassified, which might lead to delayed specific treatment and unfavourable clinical outcomes. In addition, conventional methods could lack sensitivity and specificity for early diagnosis. Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory]. Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration, blood by venous puncture and tissue specimen by surgery. The investigators hypothesize that in challenging situations, novel biomarkers detected from synovial fluid or articular tissues using both conventional (e.g. histology, immunodetection, PCR) and innovative (e.g. Raman spectroscopy, nanospectroscopy) laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases.Read full original descriptionShow less
"Translating Articular Biomarkers Into Diagnoses"
Early diagnosis is a key factor in the prevention and management of rheumatic diseases. Rheumatic diseases are classically diagnosed based on criteria combining clinical, biological and radiological features. However, in up to 20% of the cases, diagnoses remain unstated and underlying rheumatic diseases unclassified, which might lead to delayed specific treatment and unfavourable clinical outcomes. In addition, conventional methods could lack sensitivity and specificity for early diagnosis. Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory]. Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration, blood by venous puncture and tissue specimen by surgery. The investigators hypothesize that in challenging situations, novel biomarkers detected from synovial fluid or articular tissues using both conventional (e.g. histology, immunodetection, PCR) and innovative (e.g. Raman spectroscopy, nanospectroscopy) laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases.
Inclusion: Age ≥ 18 years; Inflammatory and non-inflammatory bone and joint diseases requiring synovial fluid aspiration and/or joint replacement; Collection of non-opposition; Affiliated to or beneficiary of social security.
Exclusion: Neoadjuvant therapy; Inability to speak and/or read French; Patients under tutor or curatorship; Protected adults,; Patients benefiting of State Medical Aid.